Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eyenovia : to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021

07/19/2021 | 07:02am EDT

Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and “Lunch with LifeSci Featuring Eyenovia” events

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, “Presbyopia: Everybody gets it... but can it be fixed?”

The company recently successfully completed its Phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its touchless, microdose Optejet® dispenser, for on demand improvement in near vision in patients with presbyopia.

In addition, management delivered two business and clinical update presentations; replay links to both can be found below.

Details of the Eyecelerator panel are below:


Presbyopia: Everybody gets it…but can it be fixed?


Mandalay Bay South Convention Center, Las Vegas
Oceanside Ballroom CD, Level 2


Thursday, July 22, 2021


2:15pm PT (5:15pm ET)

Business and Clinical Update Presentations:

Eyenovia’s management team recently hosted two comprehensive business and clinical update presentations:

A replay of the “Lunch with LifeSci Featuring Eyenovia” event, which took place on July 13, can be found here.

A replay of the Ladenburg Thalmann presentation, which took place on July 14, can be found here.

About Eyecelerator

Eyecelerator is a partnership between the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology to connect entrepreneurs, investors, businesses and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes. For more information, visit https://eyecelerator.com.


ASCRS is an international educational society with ophthalmic surgeons at every career stage. Its mission is to empower anterior segment surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to education, advocacy and philanthropy. For more information, visit ascrs.org.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company’s lead product candidate, Mydcombi™ (tropicamide/phenylephrine fixed combination) for use in diagnostic eye exams, has an FDA PDUFA date of October 28, 2021. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

© Business Wire 2021
All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commerci..
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evaluating Micr..
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
08/11Eyenovia Reports Second Quarter 2021 Financial Results
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 3,49 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,10x
Yield 2021 -
Capitalization 148 M 148 M -
Capi. / Sales 2021 42,4x
Capi. / Sales 2022 14,8x
Nbr of Employees 33
Free-Float 63,8%
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,70 $
Average target price 15,67 $
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-9.41%142
JOHNSON & JOHNSON1.74%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.71%231 668